Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. - Wikidata - awgldk - TriplyDB

Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma.

Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma.

http://www.wikidata.org/entity/Q35988122

about

The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations SKINOMICS: Transcriptional Profiling in Dermatology and Skin Biology Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials Prognostic and predictive biomarkers: tools in personalized oncology.Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene.CXCR4 pathway associated with family history of melanoma.Distinct molecular features of different macroscopic subtypes of colorectal neoplasms Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma.Automated universal BRAF state detection within the activation segment in skin metastases by pyrosequencing-based assay U-BRAF(V600)BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy.Variations of BRAF mutant allele percentage in melanomas PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques.BRAFV600E immunopositive melanomas show low frequency of heterogeneity and association with epithelioid tumor cells: a STROBE-compliant article.BRAF pyrosequencing analysis aided by a lookup table.Melanoma brain metastases and vemurafenib: need for further investigation.A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors.A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status.BRAF mutation testing in clinical practice.Skinomics: past, present and future for diagnostic microarray studies in dermatology.A new look at drugs targeting malignant melanoma--an application for mass spectrometry imaging.Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF.Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.Reply: Intra-patient heterogeneity of BRAF mutation status: fact or fiction?Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis.

P2860

Q21133611-081A9782-B007-403D-BE7A-CEC21D6A34A3 Q24618486-5A60E34D-2003-4A19-BB92-54699B868EC6 Q28728961-8D656EED-C581-46C0-91EE-A65FA73CFCE3 Q28730438-4F017C49-E92C-4ACB-9674-492D87DF7BC9 Q33651583-697756E2-2B68-40D2-AF28-21501200BE0B Q33772206-1ED1AF97-249E-4689-8C15-1A4DA38B0DE9 Q33909518-7358B163-9F08-4DB6-8BE4-539884976897 Q34004693-1B3FDCEE-DE3F-40DC-AEBC-79A1EE601BAB Q34049618-FDCF6C54-F192-4C00-8EF4-6797EFB9B91E Q34222257-726BE0DF-05F3-40B9-895A-53A0CA74D630 Q34650871-4A62B31E-CE1E-40FE-9FDE-80BEF085B0D6 Q34667825-92D6F68C-66B1-463B-A9D0-6C0C229649DC Q34970350-8D9DC3D9-410B-4D03-8982-1D849F6038E7 Q35187723-F89E6159-DBFB-46FF-BEFF-0A0228611FB3 Q35233751-B613AED3-88D7-4CC1-B847-63D93DA42197 Q35682567-B680A122-391D-4DB9-A0C2-40B40ED13B2F Q35953893-40F252C5-6E4D-40CA-B2B4-845256834EBE Q36058758-7E88D9DE-D17A-4418-B05B-A201FBE39EC0 Q36154050-C89637C6-AE43-48AF-8FA7-39BD1F9EB0FC Q36276150-617DB1E1-696D-4476-AE9E-330A34633588 Q36512866-477074A7-E65C-4B80-90E8-A1B18BD4E682 Q36764374-7F95DE67-C074-467C-8430-364C07AE34BF Q36896131-6B47E76A-609B-44A9-94C3-5EDCA7C7CCEB Q37042015-BA19B705-33CC-4BE9-80CB-33BD8128282B Q37151106-42E9C956-9504-46BD-8E32-4F3734FCF532 Q37164443-56FEA406-933C-48B0-B599-0A030F3C9012 Q37375271-0A142440-4267-4660-9EB3-313D1C7C9540 Q37505185-A39E1B8B-2EA5-411A-8ADE-A349A7EB658C Q37600941-AE946E1B-AE53-436F-9C9F-075DB466D65F Q37988572-02821158-01C9-4AC8-B367-A426D65F9C81 Q38154933-29C36D8B-AAAA-4ABA-A6AF-E92213D74CDF Q38232032-8AA83340-974D-42BF-9052-4B3B13D60DE1 Q38412630-76D1F826-B565-4E97-981C-7368737826A0 Q39100916-75F65C30-9851-4E89-BE18-F1C2A53A5BC1 Q39105498-E6A130CF-C150-4254-8B6E-D0D07065B406 Q41874659-2B69DC10-A983-46FC-BD27-390274B81223 Q42947925-5768A4F6-AE36-4872-A40C-807A2DA5F368 Q44932116-B3E551EA-EE2C-4A80-9CE2-44DE71D5327D Q47978745-1677D257-53E3-44BD-9106-6FA4F76A9C78 Q54291229-9B47697E-871E-46CA-B6B7-F5AC8C85044F

P2860

Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma.

http://www.wikidata.org/entity/Q35988122

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Application of a BRAF pyrosequ ...... nalysis in malignant melanoma.

@ast

Application of a BRAF pyrosequ ...... nalysis in malignant melanoma.

@en

type

label

Application of a BRAF pyrosequ ...... nalysis in malignant melanoma.

@ast

Application of a BRAF pyrosequ ...... nalysis in malignant melanoma.

@en

prefLabel

Application of a BRAF pyrosequ ...... nalysis in malignant melanoma.

@ast

Application of a BRAF pyrosequ ...... nalysis in malignant melanoma.

@en

P1433

Q35988122-01FC869F-6DCF-4963-B83B-DF172F94847D

P1476

Q35988122-C43844CC-B58D-4885-93AB-A98BCD49B93E

P2093

Q35988122-29FC95E4-A193-4238-9816-2CD8902BC28E

Q35988122-2BF0EB22-B6C1-46D0-9212-59B16D25F373

Q35988122-2EEBA592-0134-4775-B843-C1810CDB7588

Q35988122-48EE43AF-7BD6-48F1-9081-E8EB1042B7E8

Q35988122-57785EE9-69F5-48DF-8521-7750292FE548

Q35988122-8063D8F0-BB28-4AD3-9A3B-D7E19B3C821B

Q35988122-ACE0AC3E-CD02-4F19-ADA5-CBE6D4564798

Q35988122-E9FDDB28-E04E-4E33-9A53-E738649DE842

P2860

Q35988122-01A199F4-AABB-4F31-A413-A65D35248413

Q35988122-0F2A63D9-4010-4580-958D-2CBC9A82155E

Q35988122-144CEADA-18C1-47F3-81E7-05D1CBF05480

Q35988122-1774E85B-4F84-44FA-9B27-40D8BA5815E2

Q35988122-183EDEC8-0AE1-4DD8-81CE-60ABB11A910D

Q35988122-1A13300D-11CB-4E0A-868E-20A68E3674A8

Q35988122-1B822E76-211D-4130-86D1-6B54E3FEA7C6

Q35988122-20BB2B00-4572-4B8F-8A79-C4F822A0FE65

Q35988122-22840167-D6CE-46BB-9FF8-95F303B26F4A

Q35988122-3A3EAFA4-C04C-410B-ADA9-679D2A6BFEA5

P304

Q35988122-6F259A44-7119-4BA5-81FF-0C89F4228701

P31

Q35988122-C3CC73CF-986F-4D46-9E90-B08A9885ABED

P356

Q35988122-2E453E36-4017-452F-8BCA-966195B43861

P433

Q35988122-59B8711A-D193-492F-986D-91321B6EE28F

P478

Q35988122-3C4F065C-4333-4789-9264-AF2FF245D5F4

P50

Q35988122-6AFBDB94-0108-4500-8DD9-29B5BA67A172

Q35988122-B2EAFA20-4B4F-4A74-9F6E-B6A33B41FA9E

P577

Q35988122-D23EBCCE-300E-4BD9-824C-51F7366D4F83

P5875

Q35988122-6B728ED1-82CF-4D65-B83B-74818EB6D766

P698

Q35988122-3580143D-39E8-4A6E-9AE0-E875A8FF088A

P932

Q35988122-9DF7661F-EC3F-48DA-8D2E-5A37F6B88D05

P356

JMOLDX.2007.060191

P1433

The Journal of Molecular Diagnostics

P1476

Application of a BRAF pyrosequ ...... nalysis in malignant melanoma.

@en

P2093

Angelica Medina

http://www.w3.org/2001/XMLSchema#string

Cynthia Spittle

http://www.w3.org/2001/XMLSchema#string

Eric Rappaport

http://www.w3.org/2001/XMLSchema#string

M Renee Ward

http://www.w3.org/2001/XMLSchema#string

Marcia S Brose

http://www.w3.org/2001/XMLSchema#string

Phyllis A Gimotty

http://www.w3.org/2001/XMLSchema#string

Richard Letrero

http://www.w3.org/2001/XMLSchema#string

Robin H Edwards

http://www.w3.org/2001/XMLSchema#string

P2860

Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

Mutations of the BRAF gene in human cancer

BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

Guilty as charged: B-RAF is a human oncogene

BRAF mutation predicts sensitivity to MEK inhibition

A gain-of-function mutation of JAK2 in myeloproliferative disorders

High-resolution identification of chromosomal abnormalities using oligonucleotide arrays containing 116,204 SNPs.

BRAF as a potential therapeutic target in melanoma and other malignancies.

Absence of BRAF mutations in UV-protected mucosal melanomas.

P304

464-471

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2353/JMOLDX.2007.060191

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Meenhard Herlyn

Katherine L Nathanson

P577

2007-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6149866

http://www.w3.org/2001/XMLSchema#string

P698

17690212

http://www.w3.org/2001/XMLSchema#string

P932

1975103

http://www.w3.org/2001/XMLSchema#string